Evaluation of in vivo interactions in mice between flurazepam and two neuroactive steroids.
The development of neuroactive steroids as anticonvulsant medications may be useful both as a primary treatment and as an adjuvant to other anticonvulsants. They may be limited, however, by sedative and ataxic side effects. In the current study, 3 alpha-hydroxy-5 beta-pregnan-20-one and alfaxalone, two prototypic neuroactive steroids, were shown to potentiate the ability of flurazepam to antagonize electrically precipitated tonic hindlimb extension in mice at doses that by themselves had little antiseizure efficacy. While alfaxalone alone lacked motor incoordinating effects at a dose (18.0 mg/kg) that potentiated the antiseizure efficacy of flurazepam, the same dose of 3 alpha-hydroxy-5 beta-pregnan-20-one possessed both the ability to potentiate flurazepam's anticonvulsant effect and disrupt mouse rotorod performance. The data suggest that allosteric interactions that have been described in vitro between neuroactive steroids and other modulators of the GABAA receptor complex may have relevance for the intact animal. Finally, the data also suggest that neuroactive steroids could be developed as short-lived adjuvant antiseizure medications in certain critical situations (e.g., medication-refractory status epilepticus). However, the motor incoordinating effects resulting from the combination of neuroactive steroids and flurazepam suggest that their usefulness as adjuvant medications in the chronic therapy of seizure disorders may be limited.
Deutsch
S I
SI
Psychiatry Service (116A), Department of Veterans Affairs Medical Center, Washington, DC 20422, USA.
Rosse
R B
RB
Steinberg
K
K
Morn
C
C
Koetzner
L
L
Riggs
R
R
Mastropaolo
J
J
D000818:Animals; D000927:Anticonvulsants / Q000494:pharmacology*; D001522:Behavior, Animal / Q000187:drug effects; D004347:Drug Interactions; D004558:Electric Stimulation; D005479:Flurazepam / Q000494:pharmacology*; D018757:GABA Modulators / Q000494:pharmacology; D006993:Hypnotics and Sedatives / Q000494:pharmacology*; D008297:Male; D051379:Mice; D009043:Motor Activity / Q000187:drug effects; D011277:Pregnanediones / Q000494:pharmacology*; D011280:Pregnanolone / Q000494:pharmacology*; D011963:Receptors, GABA-A / Q000502:physiology; D012640:Seizures / Q000517:prevention & control*
D000927:Anticonvulsants; D018757:GABA Modulators; D006993:Hypnotics and Sedatives; D011277:Pregnanediones; D011963:Receptors, GABA-A; C006477:alphaxalone; D011280:Pregnanolone; D005479:Flurazepam